Qiagen Licenses Biomarker IP from Johns Hopkins | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that its DxS subsidiary has licensed a biomarker from Johns Hopkins University that it plans to use to develop PCR-based companion diagnostic tests for cancer.

Studies have shown that the PI3K gene that Qiagen licensed has mutations that could serve as predictive biomarkers for the success of some treatments for patients with lung, breast, colorectal, and other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.